GenScript Biotech Corporation has expanded its cGMP manufacturing capacity for sgRNA and non-viral DNA payloads with a new, state-of-the-art facility in Zhenjiang, Jiangsu, China. This latest expansion provides biopharma companies and gene and cell therapeutic discovery startups a fast-turnaround source of the quality components needed to advance novel therapies from the bench to the clinic and onto the market in less time. The move by GenScript, a market leader in the synthesis of cGMP-quality CRISPR sgRNA and HDR (homology-directed repair) templates, positions GenScript as the top supplier with the capacity to shorten the traditionally long wait times for crucial genetic material used to advance life-saving gene and cell therapies -- and to reduce the significant financial risk undertaken by the companies that develop such therapies.

GenScript has a proven track record of providing cGMP-quality sgRNA and non-Viral DNA payloads, along with full batch records, documentation, and the regulatory support needed for gene- and cell-therapy development and successful IND filing. GenScript's ongoing commitment to meet the needs of research scientists. In 2020, GenScript established a 21,500 sq.

ft. cGMP plant in Nanjing, comprising five cGMP production lines for synthetic CRISPR sg RNA and non-viral DNA cargos. As of April 2023, GenScript has delivered 56 batches of cGMP quality gene editing products to global biotechnology and pharmaceutical companies in the gene and cell therapy field, supporting 18 project applications, five of which have received IND approvals.

This recent expansion adds 400,000 sq.ft. of cGMP manufacturing space in Zhenjiang, bringing onstream four additional production lines equipped to deliver up to gram quantities of sgRNA or hundreds of milligrams of sgRNA or dsDNA per batch, respectively, with superior purity.